Related Experiment Videos
French field experience with buprenorphine.
Marc Auriacombe1, Mélina Fatséas, Jacques Dubernet
1Department of Psychiatry and Addiction, Victor Pachon Medical School, Université Victor Segalen Bordeaux 2, Bordeaux, France. marc.auriacombe@labopsy.u-bordeaux2.fr
The American Journal on Addictions
|June 19, 2004
Summary
France
Area of Science:
- Public Health
- Pharmacology
- Addiction Medicine
Background:
- Opiate abuse treatment is limited in Europe due to regulations.
- France has expanded access to buprenorphine (BUP) for opiate addiction treatment.
Purpose of the Study:
- To evaluate the impact of liberal buprenorphine prescribing policies in France.
- To compare buprenorphine treatment outcomes with methadone policies.
Main Methods:
- Analysis of buprenorphine prescription data and patient outcomes in France since 1995.
- Comparison of treatment retention, illicit drug use, overdose deaths, and neonatal withdrawal.
Main Results:
- Buprenorphine (BUP) treatment reached significantly more patients than methadone.
- Supervised dosing improved treatment retention and reduced heroin use.
- Opiate overdose deaths declined by 79% after BUP introduction.
- Neonatal opiate withdrawal was less severe with BUP compared to methadone.
Conclusions:
- Liberal buprenorphine prescribing policies in France have expanded treatment access and yielded public health benefits.
- The French model challenges restrictive buprenorphine regulations in other countries.
- Supervised dosing and integrated healthcare systems may enhance buprenorphine treatment effectiveness.